View Older Stories View More Recent Stories

Mar 25, 2025 06:45AM Merck (MRK) Enters Exclusive License Agreement for HRS-5346
Mar 25, 2025 06:45AM Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Mar 24, 2025 03:30PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 23, 2025 12:18PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 22, 2025 11:24AM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 21, 2025 11:18AM ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 19, 2025 06:52PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 19, 2025 06:45AM Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
Mar 18, 2025 06:47PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 17, 2025 06:41PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 16, 2025 05:22PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 15, 2025 05:22PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 14, 2025 05:17PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 12, 2025 11:26AM Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
Mar 11, 2025 10:05PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 11, 2025 06:45AM Merck (MRK) Unveils New Facility to Increase Vaccine Production Capacity
Mar 11, 2025 06:45AM Merck Unveils New Facility to Increase Vaccine Production Capacity
Mar 9, 2025 01:21PM ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 7, 2025 11:05PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 6, 2025 07:57PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 5, 2025 07:52PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 4, 2025 07:46PM TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 3, 2025 07:18PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 2, 2025 07:02PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 1, 2025 07:01PM ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 28, 2025 06:56PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 27, 2025 06:50PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 26, 2025 05:28PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 25, 2025 05:23PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 25, 2025 06:45AM Merck (MRK) Granted FDA Priority Review to Application for KEYTRUDA Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Feb 25, 2025 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinom
Feb 24, 2025 02:23PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 24, 2025 06:45AM Merck to Participate in the TD Cowen 45th Annual Health Care Conference
Feb 22, 2025 10:17PM ROSEN, A LEADING FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 21, 2025 07:28PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 19, 2025 03:44PM ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 18, 2025 06:45AM Merck (MRK) Reports WELIREG Received First European Commission Approval for Two Indications
Feb 18, 2025 06:45AM WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
Feb 17, 2025 02:04PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 15, 2025 09:25PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 14, 2025 02:30PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 6, 2025 06:45AM Merck (MRK) Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin
Feb 6, 2025 06:45AM Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large
Feb 4, 2025 06:30AM Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
Jan 31, 2025 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for CAPVAXIVE
Jan 31, 2025 06:45AM Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
Jan 30, 2025 06:45AM Merck (MRK) to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR Early and Move to Final Analysis
Jan 30, 2025 06:45AM Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Jan 28, 2025 01:28PM Merck (MRK) Announces $10B Share Buyback
Jan 28, 2025 01:28PM Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
View More Recent Stories View Older Stories